Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

Similar articles for PubMed (Select 21665955)

1.

Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.

Lenihan D, Suter T, Brammer M, Neate C, Ross G, Baselga J.

Ann Oncol. 2012 Mar;23(3):791-800. doi: 10.1093/annonc/mdr294. Epub 2011 Jun 10.

2.

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.

Swain SM, Ewer MS, Cortés J, Amadori D, Miles D, Knott A, Clark E, Benyunes MC, Ross G, Baselga J.

Oncologist. 2013;18(3):257-64. doi: 10.1634/theoncologist.2012-0448. Epub 2013 Mar 8.

3.

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L.

J Clin Oncol. 2010 Mar 1;28(7):1138-44. doi: 10.1200/JCO.2009.24.2024. Epub 2010 Feb 1.

4.

HER-dimerization inhibitors: evaluating pertuzumab in women's cancers.

Kristjansdottir K, Dizon D.

Expert Opin Biol Ther. 2010 Feb;10(2):243-50. doi: 10.1517/14712590903514090. Review.

PMID:
20001562
5.

Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.

Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP.

J Am Coll Cardiol. 2012 Dec 18;60(24):2504-12. doi: 10.1016/j.jacc.2012.07.068. Epub 2012 Nov 14.

6.

Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.

Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J.

J Clin Oncol. 2005 Nov 1;23(31):7811-9.

7.

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.

Gianni L, Lladó A, Bianchi G, Cortes J, Kellokumpu-Lehtinen PL, Cameron DA, Miles D, Salvagni S, Wardley A, Goeminne JC, Hersberger V, Baselga J.

J Clin Oncol. 2010 Mar 1;28(7):1131-7. doi: 10.1200/JCO.2009.24.1661. Epub 2010 Feb 1.

8.

The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.

Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, Tian G, Kirkpatrick ID, Singal PK, Krahn M, Grenier D, Jassal DS.

J Am Coll Cardiol. 2011 May 31;57(22):2263-70. doi: 10.1016/j.jacc.2010.11.063.

9.

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

Cortés J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, Verma S, Albanell J, Conte P, Lluch A, Salvagni S, Servent V, Gianni L, Scaltriti M, Ross GA, Dixon J, Szado T, Baselga J.

J Clin Oncol. 2012 May 10;30(14):1594-600. doi: 10.1200/JCO.2011.37.4207. Epub 2012 Mar 5.

10.

Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis.

Drucker AM, Wu S, Dang CT, Lacouture ME.

Breast Cancer Res Treat. 2012 Sep;135(2):347-54. doi: 10.1007/s10549-012-2157-7. Epub 2012 Jul 11. Review.

PMID:
22782294
11.

Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.

Telli ML, Hunt SA, Carlson RW, Guardino AE.

J Clin Oncol. 2007 Aug 10;25(23):3525-33. Review.

PMID:
17687157
12.

Trastuzumab containing regimens for early breast cancer.

Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D'Amico R.

Cochrane Database Syst Rev. 2012 Apr 18;4:CD006243. doi: 10.1002/14651858.CD006243.pub2. Review.

PMID:
22513938
13.

Cardiac toxicity of ErbB2-targeted therapies: what do we know?

Perez EA.

Clin Breast Cancer. 2008 Mar;8 Suppl 3:S114-20. Review.

PMID:
18777950
14.

CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.

Baselga J, Swain SM.

Clin Breast Cancer. 2010 Dec 1;10(6):489-91. doi: 10.3816/CBC.2010.n.065.

PMID:
21147694
15.

Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.

Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, Schiff R.

J Natl Cancer Inst. 2007 May 2;99(9):694-705.

16.

Management of trastuzumab-related cardiac dysfunction.

Carver JR.

Prog Cardiovasc Dis. 2010 Sep-Oct;53(2):130-9. doi: 10.1016/j.pcad.2010.07.001. Review.

PMID:
20728700
17.

Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.

Bengala C, Zamagni C, Pedrazzoli P, Matteucci P, Ballestrero A, Da Prada G, Martino M, Rosti G, Danova M, Bregni M, Jovic G, Guarneri V, Maur M, Conte PF; Gruppo Italiano Trapianto Midollo Osseo (GITMO) Group.

Br J Cancer. 2006 Apr 10;94(7):1016-20.

18.

Targeted therapies in breast cancer: are heart and vessels also being targeted?

Criscitiello C, Metzger-Filho O, Saini KS, de Castro G Jr, Diaz M, La Gerche A, de Azambuja E, Piccart-Gebhart MJ.

Breast Cancer Res. 2012 Jun 19;14(3):209. Review.

19.
20.

Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.

Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, de Vries DJ, Eberhard DA, Lyons B, Lutzker SG, Johnson BE.

Clin Cancer Res. 2007 Oct 15;13(20):6175-81.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk